GAMMA Investing LLC Grows Stock Position in Doximity, Inc. $DOCS

GAMMA Investing LLC grew its holdings in Doximity, Inc. (NASDAQ:DOCS) by 5.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,981 shares of the company’s stock after acquiring an additional 165 shares during the period. GAMMA Investing LLC’s holdings in Doximity were worth $183,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Doximity by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 12,194,492 shares of the company’s stock valued at $707,646,000 after purchasing an additional 990,923 shares during the period. Invesco Ltd. increased its stake in Doximity by 54.8% in the 1st quarter. Invesco Ltd. now owns 1,969,326 shares of the company’s stock worth $114,280,000 after buying an additional 696,923 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Doximity by 130.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,966,801 shares of the company’s stock valued at $114,133,000 after acquiring an additional 1,113,076 shares during the period. Fuller & Thaler Asset Management Inc. lifted its position in shares of Doximity by 9.5% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,730,282 shares of the company’s stock valued at $100,408,000 after acquiring an additional 150,574 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Doximity by 8.2% in the first quarter. Bank of New York Mellon Corp now owns 1,137,912 shares of the company’s stock valued at $66,033,000 after acquiring an additional 86,135 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Doximity Stock Up 0.1%

Doximity stock opened at $74.46 on Monday. Doximity, Inc. has a 52-week low of $40.87 and a 52-week high of $85.21. The firm’s fifty day moving average is $66.01 and its 200 day moving average is $60.33. The company has a market cap of $13.95 billion, a price-to-earnings ratio of 74.46, a PEG ratio of 4.10 and a beta of 1.37.

Doximity (NASDAQ:DOCS) last posted its earnings results on Thursday, August 7th. The company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. The business’s revenue was up 15.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.28 EPS. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. On average, equities research analysts anticipate that Doximity, Inc. will post 0.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Doximity

In other news, Director Timothy S. Cabral sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $75.00, for a total value of $1,500,000.00. Following the completion of the sale, the director directly owned 3,221 shares of the company’s stock, valued at $241,575. This trade represents a 86.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Regina M. Benjamin sold 5,000 shares of Doximity stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $70.50, for a total value of $352,500.00. Following the completion of the transaction, the director owned 19,839 shares of the company’s stock, valued at approximately $1,398,649.50. This trade represents a 20.13% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,000 shares of company stock worth $2,581,880 over the last ninety days. Company insiders own 31.30% of the company’s stock.

Analyst Ratings Changes

DOCS has been the subject of several research analyst reports. KeyCorp increased their target price on Doximity from $65.00 to $70.00 and gave the stock an “overweight” rating in a research report on Monday, July 14th. Truist Financial increased their price objective on shares of Doximity from $52.00 to $61.00 and gave the company a “hold” rating in a report on Thursday, July 17th. Raymond James Financial set a $75.00 target price on shares of Doximity in a report on Wednesday, September 10th. Wells Fargo & Company upped their target price on shares of Doximity from $55.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Monday, August 4th. Finally, Canaccord Genuity Group lifted their price target on shares of Doximity from $59.00 to $67.00 and gave the company a “hold” rating in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $67.42.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.